Celiprolol in systemic hypertension

William H. Frishman, Walter Flamenbaum, James Schoenberger, Gary L. Schwartz, Donald G. Vidt, Gilberto S. Neri, Steven Greenberg, Eliot Lazar, John C. Godfrey, Annette Stevenson, Kim D. Lamon, Yueh Chang, David J. Magner

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

The safety and efficacy of orally administered celiprolol, a new β1-selective adrenergic blocking drug with peripheral β2-agonist properties, were assessed in 91 patients with mild to moderate systemic hypertension (supine diastolic blood pressure [BP] 95 to 114 nun Hg without medication) using a placebo-controlled, double-blind, randomized, titration-to-effect study design. All patients received placebo for 4 weeks and were then randomized to receive placebo (n = 46) or once-daily celiprolol (n = 45), which was titrated every 2 weeks (200, 400, 600 mg/day) over a 6-week period to achieve a reduction in supine diastolic BP to ≤90 mm Hg. Plasma lipids and lipoproteins were also assessed at baseline, during placebo and after randomization to active therapy in a subgroup of patients. Compared with placebo, celiprolol reduced supine and standing BP (reduction of supine BP -0.4 -2.1 mm Hg with placebo, -5.7 -6.4 with celiprolol, p < 0.05; reduction of standing BP -1.7 -1.0 with placebo, -7.2 -4.9 with celiprolol, p < 0.05). Supine heart rate was reduced by 6.8 beats/min with celiprolol compared with 2.0 beats/min with placebo (p < 0.05). No differences were seen when the effects of placebo and celiprolol on plasma lipoproteins were compared. Celiprolol is a safe, effective and well tolerated once-daily antihypertensive drug and has no detrimental effects on plasma lipids.

Original languageEnglish (US)
Pages (from-to)839-842
Number of pages4
JournalThe American journal of cardiology
Volume63
Issue number12
DOIs
StatePublished - Apr 1 1989

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Celiprolol in systemic hypertension'. Together they form a unique fingerprint.

  • Cite this

    Frishman, W. H., Flamenbaum, W., Schoenberger, J., Schwartz, G. L., Vidt, D. G., Neri, G. S., Greenberg, S., Lazar, E., Godfrey, J. C., Stevenson, A., Lamon, K. D., Chang, Y., & Magner, D. J. (1989). Celiprolol in systemic hypertension. The American journal of cardiology, 63(12), 839-842. https://doi.org/10.1016/0002-9149(89)90053-2